Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.67 |
| ▸ | HPGD | P15428 | 3/20 | 0.67 |
| ▸ | RAB9A | P51151 | 3/20 | 0.67 |
| ▸ | NPC1 | O15118 | 2/20 | 0.67 |
| ▸ | LMNA | P02545 | 2/20 | 0.67 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.67 |
| ▸ | HTT | P42858 | 1/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.61 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | GLA | P06280 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | ATM | Q13315 | 1/20 | 0.56 |
| ▸ | MMP13 | P45452 | 5/20 | 0.56 |
| ▸ | MMP2 | P08253 | 4/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5842371 | 0.89 | KDM4E (0.69) | KDM4EALDH1A1HPGDRAB9ANPC1 | |
| SCHEMBL27969737 | 0.87 | KDM4E (0.69) | KDM4EALDH1A1HPGDRAB9ANPC1 | |
| SCHEMBL5841102 | 0.86 | KDM4E (0.72) | KDM4EALDH1A1HPGDRAB9ANPC1 | |
| SCHEMBL9263164 | 0.86 | KDM4E (0.80) | KDM4EALDH1A1HPGDRAB9ANPC1 | |
| SCHEMBL862913 | 0.83 | KDM4E (0.74) | KDM4EALDH1A1HPGDRAB9ANPC1 | |
| SCHEMBL3031260 | 0.81 | KDM4E (0.72) | KDM4EALDH1A1HPGDRAB9ANPC1 | |
| SCHEMBL5843616 | 0.81 | KDM4E (0.65) | KDM4EALDH1A1HPGDRAB9ANPC1 | |
| SCHEMBL13853762 | 0.81 | KDM4E (0.67) | KDM4EALDH1A1HPGDRAB9ANPC1 | |
| SCHEMBL5472257 | 0.81 | PDGFRB (0.68) | KDM4EALDH1A1HPGDRAB9ANPC1 | |
| SCHEMBL75327 | 0.81 | KDM4E (1.00) | KDM4EALDH1A1HPGDRAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7071332-B2 | Indolinone derivatives as protein kinase/phosphatase inhibitors | SUGEN, INC. (US) | 2006-07-04 | — | — | US | disclosed |
| US-20040147586-A1 | Indolinone derivatives as protein kinase/phosphatase inhibitors | SUGEN, INC. | 2004-07-29 | — | — | US | disclosed |
| US-6706709-B2 | TREATING, FOR EXAMPLE, PROLIFERATIVE DISORDERS INCLUDING CANCER | SUGEN, INC. | 2004-03-16 | — | — | US | disclosed |
| EP-1294688-A2 | INDOLINONE DERIVATIVES AS PROTEIN KINASE/PHOSPHATASE INHIBITORS | Sugen, Inc. (US) | 2003-03-26 | — | — | EP | disclosed |
| US-20020052369-A1 | Indolinone derivatives as protein kinase/phosphatase inhibitors | SUGEN, INC. | 2002-05-02 | — | — | US | disclosed |
| WO-2001094312-A2 | INDOLINONE DERIVATIVES AS PROTEIN KINASE/PHOSPHATASE INHIBITORS | SUGEN, INC. (US) | 2001-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147586-A1 | Indolinone derivatives as protein kinase/phosphatase inhibitors | PHKA1, PHKA2, PDPK1 | KDM4E 948/4885ALDH1A1 2164/4885HPGD 859/4885 |
| US-20020052369-A1 | Indolinone derivatives as protein kinase/phosphatase inhibitors | PHKA1, PHKA2, PDPK1 | KDM4E 948/4885ALDH1A1 2164/4885HPGD 859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.